Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$16.78 USD
-0.81 (-4.60%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $16.76 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Structure Therapeutics Inc. Sponsored ADR has a market cap of $1.01B, which represents its share price of $17.59 multiplied by its outstanding shares number of 57.34M. As a small-cap company, GPCR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
GPCR 16.78 -0.81(-4.60%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Other News for GPCR
Structure Therapeutics (GPCR) Gains Analyst Support with Buy Rating
Structure Therapeutics initiated with bullish view at Clear Street, here's why
Goldman Sachs Initiates Coverage on Structure Therapeutics (GPCR) | GPCR Stock News
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim